Free Trial
NASDAQ:BJDX

Bluejay Diagnostics (BJDX) Stock Price, News & Analysis

Bluejay Diagnostics logo
$2.60 -0.01 (-0.38%)
As of 09:53 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Bluejay Diagnostics Stock (NASDAQ:BJDX)

Advanced

Key Stats

Today's Range
$2.68
▼
$2.68
50-Day Range
$2.12
▼
$4.12
52-Week Range
$1.84
▼
$28.00
Volume
293 shs
Average Volume
536,068 shs
Market Capitalization
$2.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Bluejay Diagnostics, Inc. is a medical technology company focused on developing rapid, point-of-care diagnostic testing solutions. The company’s technology is designed to provide healthcare professionals with timely information from blood samples, supporting clinical decision-making in settings where conventional laboratory testing may take longer.

Its primary product is the Symphony system, a diagnostic platform consisting of an analyzer and disposable test cartridges. The platform is intended to measure biomarkers in whole blood and is being developed for applications including the assessment and management of serious medical conditions such as sepsis and other critical-care situations.

Bluejay Diagnostics is headquartered in Acton, Massachusetts, and serves the healthcare market through the development of diagnostic products for hospitals, clinics and other point-of-care environments. The company’s strategy centers on advancing and commercializing its Symphony technology and related assays.

AI Generated. May Contain Errors.

Bluejay Diagnostics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
18th Percentile Overall Score

BJDX MarketRank™: 
0.891102257635 of 5 stars

Bluejay Diagnostics scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bluejay Diagnostics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Bluejay Diagnostics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Bluejay Diagnostics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bluejay Diagnostics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bluejay Diagnostics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bluejay Diagnostics has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.43% of the float of Bluejay Diagnostics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bluejay Diagnostics has a short interest ratio ("days to cover") of 1.01, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bluejay Diagnostics has recently decreased by 46.06%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Bluejay Diagnostics does not currently pay a dividend.

  • Dividend Growth

    Bluejay Diagnostics does not have a long track record of dividend growth.

  • News Sentiment

    Bluejay Diagnostics has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Bluejay Diagnostics this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Bluejay Diagnostics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    6.10% of the stock of Bluejay Diagnostics is held by insiders.

  • Percentage Held by Institutions

    18.47% of the stock of Bluejay Diagnostics is held by institutions.

  • Read more about Bluejay Diagnostics' insider trading history.
Receive BJDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bluejay Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BJDX Stock News Headlines

Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
See More Headlines

BJDX Stock Analysis - Frequently Asked Questions

Bluejay Diagnostics' stock was trading at $10.6752 on January 1st, 2026. Since then, BJDX stock has decreased by 75.6% and is now trading at $2.61.

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) posted its quarterly earnings data on Thursday, November, 12th. The company reported ($1.72) earnings per share for the quarter, beating analysts' consensus estimates of ($3,520.00) by $3,518.28.

Bluejay Diagnostics shares reverse split before market open on Thursday, June 20th 2024.The 1-8 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Bluejay Diagnostics (BJDX) raised $0 in an initial public offering on Tuesday, November 9th 2021. The company issued 2,160,000 shares at $0.00 per share.

Shares of BJDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bluejay Diagnostics investors own include Pasithea Therapeutics (KTTA), Archer Aviation (ACHR), AMC Entertainment (AMC), Azitra (AZTR), Aeva Technologies (AEVA), Amarin (AMRN) and Auddia (AUUD).

Company Calendar

Last Earnings
11/12/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:BJDX
CIK
1704287
Fax
N/A
Employees
6
Year Founded
2015

Profitability

EPS (Trailing Twelve Months)
($28.44)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$6.85 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-113.79%
Return on Assets
-91.42%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.91
Quick Ratio
3.91

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$33.73 per share
Price / Book
0.08

Miscellaneous

Outstanding Shares
1,117,000
Free Float
1,049,000
Market Cap
$2.92 million
Optionable
Not Optionable
Beta
0.92

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NASDAQ:BJDX) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners